Skip to main content
SpringerLink
Log in

The predictive value of genes of the TGF-β1 pathway in multimodally treated squamous cell carcinoma of the esophagus

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Background and aim

Pretherapeutic identification of esophageal squamous cell carcinomas (ESCCs) that are likely to respond to neoadjuvant chemoradiotherapy is important in the attempt to improve the prognosis for patients. In the present study, expression of members of the transforming growth factor-β1 (TGF-β1) signaling pathway was investigated in pretherapeutic biopsies from 97 ESCCs (cT3, cN0/+, cM0) in patients who underwent neoadjuvant chemoradiotherapy (45 Gy plus cisplatin and 5-fluorouracil) and subsequent esophagectomy in the setting of a single-center prospective treatment trial.

Materials and methods

Expression of TGF-β1 and its downstream effectors Smad4 and Smad7 was assessed using quantitative reverse transcription polymerase chain reaction from RNA prepared from pretherapeutic tumor biopsies. The presence of phosphorylated Smad2 was assessed immunohistochemically.

Results

Expression of TGF-β1 (mean 7.8; range 0.0–25.7 arb. units), Smad4 (mean 0.1; range 0.0–0.4 arb. units), and Smad7 (mean 1.6; range 0.4–16.1 arb. units) varied substantially between the patients. Tumors with total or subtotal regression, as determined by histopathological examination after neoadjuvant chemoradiotherapy, showed significantly higher levels of Smad4 mRNA expression than tumors with minor or no regression (P = 0.032). TGF-β1 and Smad7 mRNA expression as well as Smad2 protein expression were of no prognostic value. Expression of the four genes under analysis also showed no impact on the overall survival. In contrast, the overall survival correlated significantly with histopathological regression (P < 0.0001) and to a minor degree also with clinical regression grading (P = 0.0254).

Interpretation

Among the parameters analyzed, only Smad4 was found to have possible predictive value for esophageal squamous cell carcinoma in patients receiving neoadjuvant chemoradiotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Levi F, Te VC, Randimbison L, La Vecchia C (2004) Trends in survival for both histologic types of esophageal cancer in Switzerland. Int J Cancer 108:638–639

    Article  CAS  PubMed  Google Scholar 

  2. van Blankenstein M, Looman CW, Hop WC, Bytzer P (2005) The incidence of adenocarcinoma and squamous cell carcinoma of the esophagus: Barrett’s esophagus makes a difference. Am J Gastroenterol 100:766–774

    Article  PubMed  Google Scholar 

  3. van Meerten E, van der Gaast A (2005) Systemic treatment for oesophageal cancer. Eur J Cancer 41:664–672

    Article  PubMed  Google Scholar 

  4. Stahl M, Stuschke M, Lehmann N et al (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310–2317

    Article  PubMed  Google Scholar 

  5. Stahl M, Wilke H, Stuschke M et al (2005) Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol 131:67–72

    Article  PubMed  Google Scholar 

  6. Brücher BLDM, Stein HJ, Zimmermann F et al (2004) Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol 30:963–971

    PubMed  Google Scholar 

  7. Lordick F, Stein HJ, Peschel C, Siewert JR (2004) Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 91:540–551

    Article  CAS  PubMed  Google Scholar 

  8. Fietkau R (2004) Definitive and neoadjuvant radiochemotherapy of squamous cell carcinoma of the oesophagus. Onkologie 27:39–44

    Article  CAS  PubMed  Google Scholar 

  9. Kawai K, Watabe S, Matsuda M, Sakamoto K, Kamano T (2005) Correlation between expression of orotate phosphoribosyl transferase and 5-fluorouracil sensitivity, as measured by apoptosis index in colorectal cancer tissue. Int J Gastrointest Cancer 35:197–204

    Article  CAS  PubMed  Google Scholar 

  10. Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S (2005) The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs. Oncol Rep 14:609–615

    CAS  PubMed  Google Scholar 

  11. Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S (2005) Apoptosis induced by 5-fluorouracil, cisplatin and paclitaxel are associated with p53 gene status in gastric cancer cell lines. Int J Oncol 26:1563–1567

    CAS  PubMed  Google Scholar 

  12. Zhang QX, Feng R, Zhang W, Ding Y, Yang JY, Liu GH (2005) Role of stress-activated MAP kinase P38 in cisplatin- and DTT-induced apoptosis of the esophageal carcinoma cell line Eca109. World J Gastroenterol 11:4451–4456

    CAS  PubMed  Google Scholar 

  13. Munro AJ, Lain S, Lane DP (2005) P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 92:434–444

    CAS  PubMed  Google Scholar 

  14. Steele RJ, Lane DP (2005) P53 in cancer: a paradigm for modern management of cancer. Surgeon 3:197–205

    Article  CAS  PubMed  Google Scholar 

  15. Brücher BL, Keller G, Werner M, Müller U, Lassmann S, Cabras AD, Fend F, Busch R, Stein H, Allescher HD, Molls M, Siewert JR, Höfler H, Specht K (2008) Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy. Int J Colorectal Dis 24:69–77

    Article  PubMed  Google Scholar 

  16. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425:577–584

    Article  CAS  PubMed  Google Scholar 

  17. Attisano L, Wrana JL (2002) Signal transduction by the TGF-beta superfamily. Science 296:1646–1647

    Article  CAS  PubMed  Google Scholar 

  18. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685–700

    Article  CAS  PubMed  Google Scholar 

  19. Stoika R, Yakymovych M, Souchelnytskyi S, Yakymovych I (2003) Potential role of transforming growth factor beta1 in drug resistance of tumor cells. Acta Biochim Pol 50:497–508

    CAS  PubMed  Google Scholar 

  20. Ewan KB, Henshall-Powell RL, Ravani SA et al (2002) Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. Cancer Res 62:5627–5631

    CAS  PubMed  Google Scholar 

  21. Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA (1994) Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest 93:892–899

    Article  CAS  PubMed  Google Scholar 

  22. Raynal S, Nocentini S, Croisy A, Lawrence DA, Jullien P (1997) Transforming growth factor-beta1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line. Int J Cancer 72:356–361

    Article  CAS  PubMed  Google Scholar 

  23. Luo K (2004) Ski and SnoN: negative regulators of TGF-beta signaling. Curr Opin Genet Dev 14:65–70

    Article  CAS  PubMed  Google Scholar 

  24. Miyazono K, Maeda S, Imamura T (2004) Coordinate regulation of cell growth and differentiation by TGF-beta superfamily and Runx proteins. Oncogene 23:4232–4237

    Article  CAS  PubMed  Google Scholar 

  25. Landstrom M, Heldin NE, Bu S et al (2000) Smad7 mediates apoptosis induced by transforming growth factor beta in prostatic carcinoma cells. Curr Biol 10:535–538

    Article  CAS  PubMed  Google Scholar 

  26. Edlund S, Bu S, Schuster N et al (2003) Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell 14:529–544

    Article  CAS  PubMed  Google Scholar 

  27. Kim KY, Kim BC, Xu Z, Kim SJ (2004) Mixed lineage kinase 3 (MLK3)-activated p38 MAP kinase mediates transforming growth factor-beta-induced apoptosis in hepatoma cells. J Biol Chem 279:29478–29484

    Article  CAS  PubMed  Google Scholar 

  28. Dai C, Yang J, Liu Y (2003) Transforming growth factor-beta1 potentiates renal tubular epithelial cell death by a mechanism independent of Smad signaling. J Biol Chem 278:12537–12545

    Article  CAS  PubMed  Google Scholar 

  29. Roberts AB, Wakefield LM (2003) The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 100:8621–8623

    Article  CAS  PubMed  Google Scholar 

  30. Elliott RL, Blobe GC (2005) Role of transforming growth factor beta in human cancer. J Clin Oncol 23:2078–2093

    Article  CAS  PubMed  Google Scholar 

  31. Fukai Y, Fukuchi M, Masuda N et al (2003) Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J Cancer 104:161–166

    Article  CAS  PubMed  Google Scholar 

  32. Zhou Q, Dong Wang L, Du F et al (2002) Changes of TGFbeta1 and TGFbetaRII expression in esophageal precancerous and cancerous lesions: a study of a high-risk population in Henan, northern China. Dis Esophagus 15:74–79

    Article  CAS  PubMed  Google Scholar 

  33. Landis MD, Seachrist DD, Montanez-Wiscovich ME, Danielpour D, Keri RA (2005) Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene 24:5173–5190

    Article  CAS  PubMed  Google Scholar 

  34. Fukuchi M, Masuda N, Miyazaki T et al (2002) Decreased Smad4 expression in the transforming growth factor-beta signaling pathway during progression of esophageal squamous cell carcinoma. Cancer 95:737–743

    Article  CAS  PubMed  Google Scholar 

  35. Lazzereschi D, Nardi F, Turco A et al (2005) A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours. Oncogene 24:5344–5354

    Article  CAS  PubMed  Google Scholar 

  36. Prunier C, Mazars A, Noe V et al (1999) Evidence that Smad2 is a tumor suppressor implicated in the control of cellular invasion. J Biol Chem 274:22919–22922

    Article  CAS  PubMed  Google Scholar 

  37. Natsugoe S, Xiangming C, Matsumoto M et al (2002) Smad4 and transforming growth factor beta1 expression in patients with squamous cell carcinoma of the esophagus. Clin Cancer Res 8:1838–1842

    CAS  PubMed  Google Scholar 

  38. Koliopanos A, Friess H, di Mola FF et al (2002) Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World J Surg 26:420–427

    Article  PubMed  Google Scholar 

  39. Sobin LH, Fleming ID (1997) TNM classification of malignant tumors, fifth edition. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80:1803–1804

    Article  CAS  PubMed  Google Scholar 

  40. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Article  CAS  PubMed  Google Scholar 

  41. Brücher BLDM, Becker K, Lordick F et al (2006) The clinical impact of histopathological response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 106:2119–2127

    Article  PubMed  Google Scholar 

  42. Specht K, Richter T, Müller U, Walch A, Höfler MW (2000) Quantitative gene expression analysis in microdissected archival tissue by real-time RT-PCR. J Mol Med 78:B27

    CAS  PubMed  Google Scholar 

  43. Specht K, Richter T, Müller U, Walch A, Werner M, Höfler H (2001) Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 158:419–429

    CAS  PubMed  Google Scholar 

  44. Rundhaug JE, Park J, Fischer SM (1997) Uncoordinated regulation of mRNA expression of the three isoforms of transforming growth factor-beta in the mouse skin carcinogenesis model. Mol Carcinog 18:115–126

    Article  CAS  PubMed  Google Scholar 

  45. Xie W, Mertens JC, Reiss DJ et al (2002) Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 62:497–505

    CAS  PubMed  Google Scholar 

  46. Xie W, Rimm DL, Lin Y, Shih WJ, Reiss M (2003) Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J 9:302–312

    Article  CAS  PubMed  Google Scholar 

  47. Joshi MB, Shirota Y, Danenberg KD et al (2005) High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 11:2215–2221

    Article  PubMed  Google Scholar 

  48. Mazars A, Lallemand F, Prunier C et al (2001) Evidence for a role of the JNK cascade in Smad7-mediated apoptosis. J Biol Chem 276:36797–36803

    Article  CAS  PubMed  Google Scholar 

  49. Osawa H, Nakajima M, Kato H, Fukuchi M, Kuwano H (2004) Prognostic value of the expression of Smad6 and Smad7, as inhibitory Smads of the TGF-beta superfamily, in esophageal squamous cell carcinoma. Anticancer Res 24:3703–3709

    CAS  PubMed  Google Scholar 

  50. Boulay JL, Mild G, Lowy A et al (2003) SMAD7 is a prognostic marker in patients with colorectal cancer. Int J Cancer 104:446–449

    Article  CAS  PubMed  Google Scholar 

  51. Kim YH, Lee HS, Lee HJ et al (2004) Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas. Ann Oncol 15:574–580

    Article  CAS  PubMed  Google Scholar 

  52. Zhang F, Laiho M (2003) On and off: proteasome and TGF-beta signaling. Exp Cell Res 291:275–281

    Article  CAS  PubMed  Google Scholar 

  53. Voorhees PM, Orlowski RZ (2006) The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 46:189–213

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We are grateful to Annette Haas and Andrea Harwardt for their skillful assistance. Financial support for this study was received from the Wilhelm Sander Foundation, Grant No. 2005.001.1.

Author information

Authors and Affiliations

  1. Department of Pathology, Technical University of Munich, Munich, Germany

    Franziska Pühringer-Oppermann

  2. Department of Pathology, Unfallkrankenhaus Berlin, Berlin, Germany

    Mario Sarbia & Nicola Ott

  3. Department of Surgery, Comprehensive Cancer Center, University of Tübingen, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany

    Björn L. D. M. Brücher

Authors
  1. Franziska Pühringer-Oppermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mario Sarbia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicola Ott
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Björn L. D. M. Brücher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Björn L. D. M. Brücher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pühringer-Oppermann, F., Sarbia, M., Ott, N. et al. The predictive value of genes of the TGF-β1 pathway in multimodally treated squamous cell carcinoma of the esophagus. Int J Colorectal Dis 25, 515–521 (2010). https://doi.org/10.1007/s00384-009-0867-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-009-0867-z

Keywords

Search

Navigation